Topics:

FDA reviewing sBLA for Pegintron for melanoma

FDA reviewing sBLA for Pegintron for melanoma

KENILWORTH, New Jersey—Schering-Plough Corporation has announced that FDA has granted priority review to its supplemental Biologics License Application for Pegintron (pegylated interferon alfa-2b) as adjuvant therapy for patients with stage III melanoma. The agent is currently approved for use in the treatment of chronic hepatitis C. The company said that FDA's Oncology Drugs Advisory Committee will discuss the application at its meeting in March.

 
Loading comments...
Please Wait 20 seconds or click here to close